Overview

A Study of IMM-101 in Combination With Checkpoint Inhibitor Therapy in Advanced Melanoma

Status:
Active, not recruiting
Trial end date:
2021-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and efficacy of the combination of IMM-101 with nivolumab.
Phase:
Phase 2
Details
Lead Sponsor:
Immodulon Therapeutics Ltd
Treatments:
Antibodies, Monoclonal
Ipilimumab
Nivolumab